Tirzepatide Long-Term Risks: What the Evidence Currently Shows

Picture yourself six months in, the honeymoon period is over, and the real question arrives

Most people who ask about tirzepatide's long-term risks aren't reading the question for the first time in week one. They ask it around the point where treatment has become routine (the weekly pen, the reduced appetite) and a quieter thought surfaces: what does a year on this medicine, or two years, actually do to the body?

The honest answer is that the longest published randomised data come from the SURMOUNT programme, which followed adults for 72 weeks (about 17 months). SURMOUNT-1, published in the New England Journal of Medicine, tracked 2,539 participants across that period and recorded both efficacy and adverse events. Serious adverse events occurred at broadly similar rates between the tirzepatide and placebo groups, which is reassuring, but 72 weeks is not ten years, and no one should pretend otherwise.

Post-marketing surveillance is where the longer picture is built. Tirzepatide holds black triangle (▼) status with the MHRA, which means healthcare professionals and patients are actively encouraged to report any suspected adverse reaction, however minor it seems. That triangular flag isn't a warning that the medicine is dangerous; it's the mechanism by which regulators accumulate real-world data beyond trial conditions. The NHS medicines page for tirzepatide gives a patient-level summary of what's known and what to watch for.

If you want a quick check you can do right now: look up tirzepatide on the MHRA's Yellow Card website, the reported adverse reactions database is publicly accessible and updated regularly. It takes under a minute and gives you a live view of what real-world monitoring is picking up.

Risks that deserve specific attention over longer treatment

Several signal areas appear consistently in both the trial data and prescriber discussions. None is grounds for alarm; all are reasons for clinical monitoring to continue.

Pancreatitis. In January 2026 the MHRA issued a Drug Safety Update covering all GLP-1 receptor agonist medicines, specifically flagging acute pancreatitis as an infrequent but potentially serious risk. The warning is practical: if you develop severe, persistent abdominal pain that radiates toward your back (with or without vomiting) stop the injection and seek urgent medical help. Most people will never experience this, but it is the one side effect where hesitation is the wrong instinct. You can find the update via the MHRA Drug Safety Update index.

Gallbladder. Rapid weight loss of any kind increases the risk of gallstones, and GLP-1 medicines may have an independent effect on gallbladder motility. SURMOUNT-1 recorded cholelithiasis (gallstones) more frequently in the tirzepatide group than placebo. Symptoms (upper-right abdominal pain, especially after fatty meals, sometimes with nausea) are worth mentioning to a prescriber promptly rather than waiting for a scheduled review.

Heart rate. A modest increase in resting heart rate has been observed with tirzepatide in trials, as with other GLP-1 agonists. For most people this is clinically insignificant, but it is monitored. The longer-term cardiovascular picture is being actively studied; unlike semaglutide, tirzepatide does not yet have a completed dedicated cardiovascular outcomes trial, though several are underway.

Thyroid. Animal studies showed C-cell tumour formation at high doses; this has not been replicated in human data, but tirzepatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2. Anyone with unexplained neck swelling or persistent hoarseness should discuss it with a clinician. For a fuller picture of the risk profile, our tirzepatide risks and side effects overview sets out each category clearly.

When to get medical help, and what doesn't need to wait

The clearest guidance from both the NHS and the prescribing community is to seek urgent medical help for any of the following during tirzepatide treatment: severe or persistent stomach pain (especially if it reaches the back), signs of an allergic reaction (swelling of the face, lips or throat, difficulty breathing), any sudden or unexplained change in vision, symptoms of dehydration following severe vomiting or diarrhoea (dizziness, very dark urine, inability to keep fluids down), and for anyone with diabetes, symptoms of very low blood glucose if combined with insulin or sulphonylurea.

Less urgent but still worth reporting at your next clinical contact: persistent nausea beyond the first few weeks of a dose level, unexplained fatigue, mood changes, or any injection-site reaction that doesn't resolve. The distinction matters because dehydration from prolonged GI upset can affect kidney function, something a prescriber wants to know about before it becomes a problem, not after.

Reporting suspected side effects through the Yellow Card scheme helps build the long-term evidence base for everyone who uses these medicines, not just you. Our prescribers discuss all of this as part of the consultation process; if you are weighing up whether tirzepatide is right for you, that conversation is the right place to start. You can also read about long-term side effects specific to tirzepatide for weight loss for more on what the extended data show.

What isn't known yet, and why that matters

Intellectual honesty about tirzepatide's long-term profile means naming the gaps as clearly as the established facts. The evidence we have is strong for the 72-week window. Beyond that, several areas remain data-sparse.

The effect of very extended treatment (three, five, ten years) on lean muscle mass is being studied but not yet established in long-term trials. Weight loss from any intervention carries a risk of muscle loss alongside fat; adequate protein intake and resistance activity are the practical counterweights, and the prescriber-led review at every repeat is the right moment to discuss this.

Bone density changes with sustained GLP-1 treatment are under investigation. Early signals suggest no significant effect, but longer-term data are needed. People with existing bone-health concerns should raise this in their consultation.

Renal function: the dehydration risk from GI side effects is well-documented in the short term. Whether sustained treatment has any independent renal effect over years is an open research question, and our page on the risks of tirzepatide covers what the current evidence does and does not tell us. Our page on tirzepatide's long-term safety evidence tracks the research as it develops.

None of these uncertainties make tirzepatide an unsafe choice for eligible adults. They make it a medicine that warrants proper clinical oversight rather than a one-off prescription and no further contact. For context on how Mounjaro fits into the broader treatment landscape, our Mounjaro overview covers the full picture, including what is currently understood about the long-term risks of Mounjaro as real-world data continues to accumulate. To speak with our prescribers about whether treatment is appropriate for you, the starting point is a free consultation.